Ogestrel 0.5/50-28 side effects by duration, gender and age - a phase IV clinical study of FDA data

Summary:

Side effects are reported by people who take Ogestrel 0.5/50-28. Common side effects include deep vein thrombosis among females.

The phase IV clinical study is created by eHealthMe based on 12 reports from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Jun, 16, 2022

12 people who take Ogestrel 0.5/50-28 and have side effects are studied.


What is Ogestrel 0.5/50-28?

Ogestrel 0.5/50-28 has active ingredients of ethinyl estradiol; norgestrel. eHealthMe is studying from 17 Ogestrel 0.5/50-28 users for its effectiveness, alternative drugs and more.

Number of Ogestrel 0.5/50-28 reports submitted per year:

Ogestrel 0.5/50-28 side effects.

Ogestrel 0.5/50-28 side effects by time on the drug*:

< 1 month:

  1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)

1 - 6 months:

  1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

  1. Abdominal distension

5 - 10 years:

n/a

10+ years:

n/a

not specified:

  1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  2. Pulmonary embolism (blockage of the main artery of the lung)
  3. Abdominal pain upper
  4. Gallbladder injury
  5. Haematochezia (passage of stools containing blood)
  6. Injection site haemorrhage (bleeding from injection site)
  7. Nausea (feeling of having an urge to vomit)

Ogestrel 0.5/50-28 side effects by gender *:

female:

  1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  2. Pulmonary embolism (blockage of the main artery of the lung)
  3. Abdominal distension
  4. Abdominal pain upper
  5. Gallbladder injury
  6. Haematochezia (passage of stools containing blood)
  7. Injection site haemorrhage (bleeding from injection site)
  8. Nausea (feeling of having an urge to vomit)

male:

n/a

Ogestrel 0.5/50-28 side effects by age (0-1 to 60+) *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  2. Pulmonary embolism (blockage of the main artery of the lung)

30-39:

  1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)

40-49:

  1. Abdominal distension
  2. Abdominal pain upper
  3. Gallbladder injury
  4. Injection site haemorrhage (bleeding from injection site)
  5. Nausea (feeling of having an urge to vomit)

50-59:

  1. Pulmonary embolism (blockage of the main artery of the lung)

60+:

n/a

* Approximation only. Some reports may have incomplete information.

Do you take Ogestrel 0.5/50-28?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



How the study uses the data?

The study is based on ethinyl estradiol; norgestrel (the active ingredients of Ogestrel 0.5/50-28) and Ogestrel 0.5/50-28 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered.

Related studies

Alternative drugs to, pros and cons of Ogestrel 0.5/50-28:

All Ogestrel 0.5/50-28 side effects from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: